The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 28, 2010
Filed:
Feb. 20, 2007
Christophe Salagnad, Les Angles, FR;
Frank Zocher, Alsbach-Hahnlein, DE;
Andreas Burgard, Frankfurt, DE;
Bernd Junker, Bad Soden, DE;
Rolf Hoerlein, Frankfurt, DE;
Thomas Stuedemann, Kelkheim, DE;
Claus-jügen Maier, Weinheim, DE;
Jochen Hachtel, Frankfurt, DE;
Wolfgang Holla, Kelkheim, DE;
Christoph Tappertzhofen, Frankfurt, DE;
Berndt Kulitzscher, Esselbach, DE;
Stephane Mutti, Le Perreux sur Marne, FR;
Christophe Salagnad, Les Angles, FR;
Frank Zocher, Alsbach-Hahnlein, DE;
Andreas Burgard, Frankfurt, DE;
Bernd Junker, Bad Soden, DE;
Rolf Hoerlein, Frankfurt, DE;
Thomas Stuedemann, Kelkheim, DE;
Claus-Jügen Maier, Weinheim, DE;
Jochen Hachtel, Frankfurt, DE;
Wolfgang Holla, Kelkheim, DE;
Christoph Tappertzhofen, Frankfurt, DE;
Berndt Kulitzscher, Esselbach, DE;
Stephane Mutti, Le Perreux sur Marne, FR;
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, DE;
Abstract
The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.